Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia.
Leung WK, Torres Chavez AG, French-Kim M, Shafer P, Mamonkin M, Hill LC, Kuvalekar M, Velazquez Y, Watanabe A, Watanabe N, Hoyos V, Lulla P, Leen AM. Leung WK, et al. Among authors: mamonkin m. Blood. 2024 Apr 25;143(17):1726-1737. doi: 10.1182/blood.2023021979. Blood. 2024. PMID: 38241630
Splendid isolation.
Wagner DL, Mamonkin M. Wagner DL, et al. Among authors: mamonkin m. Blood. 2023 Jun 1;141(22):2665-2666. doi: 10.1182/blood.2023019864. Blood. 2023. PMID: 37261853 Free article. No abstract available.
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies.
Watanabe N, Mo F, Zheng R, Ma R, Bray VC, van Leeuwen DG, Sritabal-Ramirez J, Hu H, Wang S, Mehta B, Srinivasan M, Scherer LD, Zhang H, Thakkar SG, Hill LC, Heslop HE, Cheng C, Brenner MK, Mamonkin M. Watanabe N, et al. Among authors: mamonkin m. Mol Ther. 2023 Jan 4;31(1):24-34. doi: 10.1016/j.ymthe.2022.09.003. Epub 2022 Sep 9. Mol Ther. 2023. PMID: 36086817 Free PMC article.
Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies.
Freiwan A, Zoine JT, Crawford JC, Vaidya A, Schattgen SA, Myers JA, Patil SL, Khanlari M, Inaba H, Klco JM, Mullighan CG, Krenciute G, Chockley PJ, Naik S, Langfitt DM, Mamonkin M, Obeng EA, Thomas PG, Gottschalk S, Velasquez MP. Freiwan A, et al. Among authors: mamonkin m. Blood. 2022 Dec 22;140(25):2684-2696. doi: 10.1182/blood.2021015020. Blood. 2022. PMID: 35914226 Free PMC article.
CD7 CAR: sword and shield.
Velasquez MP, Mamonkin M. Velasquez MP, et al. Among authors: mamonkin m. Blood. 2022 Jul 28;140(4):293-294. doi: 10.1182/blood.2022016595. Blood. 2022. PMID: 35900789 Free PMC article. No abstract available.
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs.
Steffin DHM, Muhsen IN, Hill LC, Ramos CA, Ahmed N, Hegde M, Wang T, Wu M, Gottschalk S, Whittle SB, Lulla PD, Mamonkin M, Omer B, Rouce RH, Heczey A, Metelitsa LS, Grilley BJ, Robertson C, Torrano V, Lapteva N, Gee AP, Rooney CM, Brenner MK, Heslop HE. Steffin DHM, et al. Among authors: mamonkin m. Blood. 2022 Jul 7;140(1):16-24. doi: 10.1182/blood.2022015728. Blood. 2022. PMID: 35325065 Free PMC article.
45 results